Literature DB >> 12182787

Radiosurgical treatment of a cerebral arteriovenous malformation in a patient with moyamoya disease: case report.

Ho Jun Seol1, Dong Gyu Kim, Chang Wan Oh, Dae Hee Han.   

Abstract

OBJECTIVE AND IMPORTANCE: A case of a cerebral arteriovenous malformation (AVM), which was treated with gamma knife surgery, in a patient with moyamoya disease is described. This is the first report of radiosurgical treatment of a cerebral AVM in a patient with moyamoya disease; the outcome was satisfactory. CLINICAL
PRESENTATION: The patient presented with frequent episodes of transient ischemic attacks and seizures. INTERVENTION: Staged encephaloduroarteriosynangiosis was performed on both sides, with an interval of 10 months. Postoperative cerebral angiography demonstrated augmented cerebral perfusion, which increased the size of the AVM nidus. The patient subsequently underwent gamma knife surgery, and the AVM completely disappeared 2 years later.
CONCLUSION: Radiosurgery may be a good treatment option for AVMs accompanying moyamoya disease, allowing the preservation of collateral vessels and the prevention of possible misery perfusion.

Entities:  

Mesh:

Year:  2002        PMID: 12182787

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  3 in total

1.  Arteriovenous malformation with an occlusive feeding artery coexisting with unilateral moyamoya disease.

Authors:  Seong Hwan Ahn; In Seong Choo; Jin Ho Kim; Hoo Won Kim
Journal:  J Clin Neurol       Date:  2010-12-31       Impact factor: 3.077

2.  Cerebral arteriovenous malformation associated with moyamoya disease.

Authors:  Jung-Hoon Noh; Je Young Yeon; Jae-Han Park; Hyung Jin Shin
Journal:  J Korean Neurosurg Soc       Date:  2014-10-31

3.  The rare association of moyamoya disease and cerebral arteriovenous malformations: a case report.

Authors:  Te-Chang Wu; Wan-Yuo Guo; Hsiu-Mei Wu; Feng-Chi Chang; Cheng-Ying Shiau; Wen-Yuh Chung
Journal:  Korean J Radiol       Date:  2008-07       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.